Isocor (isosorbide mononitrate)

Quick links

Choose a section

Quick links to important sections

Advertisements
Advertisements

Overview of Isocor (isosorbide mononitrate)

Property Description
Active ingredient Isosorbide mononitrate (Isosorbide 5-mononitrate)
Form Tablet (Oral preparation)
Pharmacological class Organic Nitrate / Vasodilator
Common use Prophylactic support of cardiovascular function
Origin Synthetic chemical compound

What Type of Medicine is Isocor (Isosorbide Mononitrate)?

Isocor is a single-ingredient, prescription-only medicine containing isosorbide mononitrate, a synthetic organic compound designated chemically as an organic nitrate. This medicine is clinically recognized as an established vasodilator and is classified as an antianginal agent.


The drug entity, isosorbide mononitrate, holds a distinctive position within the nitrate class. Unlike certain related nitrates, this compound is engineered to achieve highly predictable absorption when taken orally. This feature supports its role in stable, long-term therapeutic regimens. As a commonly available oral preparation, Isocor is positioned for use by adult patient groups requiring consistent cardiovascular support.

Form, Composition, and General Purpose

Isosorbide mononitrate is typically supplied as an oral preparation, most commonly a tablet, which can be formulated for conventional or extended-release administration. The composition is that of a single-active-ingredient product, comprising the isosorbide mononitrate component and necessary pharmaceutical excipients used for solid dosage forms.


The general purpose of this medication is to provide continuous, prophylactic treatment by consistently mediating its vasodilatory action. This sustained effect helps to reduce the heart’s workload and the demand for oxygen by the cardiac muscle, thereby supporting cardiovascular function over time. The therapeutic goal is the prevention of insufficient oxygen supply to the heart muscle. Because the action is gradual, the tablet is solely established for stable, background management, offering continuous support rather than immediate intervention.

Regulatory References

  1. antianginal agent
  2. NIH StatPearls
  3. DailyMed Listing
Advertisements

What side effects are possible with Isocor (isosorbide mononitrate)?

Possible Side Effects and Safety Information

The safety profile of Isocor (isosorbide mononitrate) is based on official government regulatory documents (e.g., FDA, EMA) and is primarily characterized by adverse reactions related to its mechanism as a vasodilator.


Adverse Reactions by Frequency

Side effects are classified according to their documented frequency in clinical studies:

Frequency Examples of Adverse Reactions (by System-Organ Class)
Very Common (ge 1/10) Headache (Nervous System)
Common (ge 1/100 to < 1/10) Dizziness, Hypotension (Vascular), Tachycardia (Cardiac), Nausea (Gastrointestinal)
Uncommon (ge 1/1,000 to < 1/100) Flushing, Vomiting, Diarrhea
Rare (ge 1/10,000 to < 1/1,000) Syncope/Fainting (Nervous System), Rash, Pruritus (Skin)
Not Known Circulatory collapse, Aggravation of Angina Pectoris, Somnolence

Time-Related Pattern: Headaches are the most frequent adverse event, typically occurring at the start of treatment and often resolving within the first week of continued use.


Serious Adverse Reactions and Safety Constraints

  • Serious Reactions: Documented serious adverse reactions include Circulatory Collapse, Severe Hypotension, and rare cases of Methemoglobinemia.
  • Safety Constraints: Isosorbide mononitrate is strictly contraindicated for use with Phosphodiesterase Type-5 (PDE5) Inhibitors (e.g., sildenafil, tadalafil) and riociguat. The combination can lead to severe, life-threatening hypotension.
  • Acute Angina: The medication is not indicated for the treatment of an acute angina attack.

Population-Specific Safety Notes

  • Pregnancy/Lactation: Safety and efficacy are not established. Use should only occur if the potential benefit outweighs the potential risk. Caution is advised for nursing women.
  • Pediatric Use: Safety and effectiveness in children have not been established.
Advertisements

Overdose and Emergency Response

Overdose and when to seek help

Feature Regulatory Documentation
Documented Manifestations Symptoms of overdose are generally the result of extreme vasodilation, including profound hypotension, persistent throbbing headache, dizziness, syncope, vertigo, palpitations, nausea, and vomiting.
Life-Threatening Outcomes Severe outcomes include circulatory collapse resulting from profound hypotension, and methemoglobinemia, which may present with cyanosis (bluish discoloration of the skin and mucous membranes) and severe breathing difficulty. Seizures have also been documented.
Emergency Actions Seek immediate medical attention or contact emergency services if an overdose is suspected or confirmed. Any manifestation of profound hypotension, circulatory collapse, or signs of methemoglobinemia requires urgent emergency care.

Official Overdose Management

Management is symptomatic and supportive treatment. For severe hypotension, official regulatory guidance recommends measures to increase central fluid volume, such as intravenous infusion of saline, and passive elevation of the patient's legs. No specific antidote is known for the primary vasodilatory effects. However, the complication of methemoglobinemia requires specific intervention with methylene blue. Continuous cardiovascular monitoring and monitoring of methemoglobin levels are required.

Regulatory documents define the isosorbide mononitrate overdose profile by explicitly linking its exaggerated vasodilatory effects to severe cardiovascular and hematologic risks. The profile mandates the need to immediately seek emergency medical care upon any suspicion of overdose, particularly if clinical signs of profound hypotension or cyanosis are observed. This guidance directs treatment toward immediate symptomatic support and specific procedural steps for reversing the methemoglobinemia complication.

Advertisements

Therapeutic Uses of Isocor (isosorbide mononitrate)

What Isocor (Isosorbide Mononitrate) Treats: Main Uses and Benefits

Isocor is commonly used in the long-term preventative management of cardiovascular symptoms. The medication is commonly used to help with conditions characterized by periods of heightened symptoms, such as angina pectoris due to coronary artery disease. It provides continuous, stable support that addresses the core symptomatic consequences of heart conditions. Isocor is considered relevant for managing chronic stable angina, assisting with symptoms related to physical discomfort, and providing adjunctive care for chronic heart conditions.

In clinical scenarios, this medicine plays a role in managing symptoms that are recurrent and linked to organ-specific functional stress. The medication is applied in addressing symptoms that interfere with daily functioning. The goal of this long-term preventative management is to support the patient during difficult episodes by easing distress and assisting with maintaining functional stability. This preventative focus helps reduce the overall symptom load.


Quick Fact: Relief for Recurrent Chest Discomfort

Isocor may assist with maintaining functional stability by easing symptoms that become more disruptive during flare-ups associated with myocardial ischemia.

Regulatory References

  1. NIH StatPearls overview
Advertisements

Eligibility and Restrictions for Use

Who can and cannot use Isocor (isosorbide mononitrate)?

Official regulatory information strictly defines which populations are eligible to use isosorbide mononitrate and for whom use is prohibited or requires special caution.

Eligibility Restrictions

Classification Populations and Conditions
Contraindicated (Must Not Use) Patients with hypersensitivity to isosorbide mononitrate, other nitrates, or nitrites. Patients taking phosphodiesterase-5 (PDE-5) inhibitors (e.g., sildenafil, tadalafil, vardenafil) or soluble guanylate cyclase (sGC) stimulators (e.g., riociguat). Concomitant use with these agents can lead to severe, life-threatening hypotension.
Use with Caution/Not Recommended Patients with severe hypotension or volume depletion. Those with acute myocardial infarction (AMI), acute circulatory failure, shock, hypertrophic cardiomyopathy, or severe anemia.

Age, Pregnancy, and Lactation Status

  • Pediatric Use: Safety and effectiveness have not been established in pediatric patients (under 18 years of age). Use is generally limited to adults.
  • Geriatric Use: Dose selection for older adults should be cautious, reflecting the greater frequency of decreased organ function.
  • Pregnancy: May be used only if clearly needed and the potential benefit is determined to justify the potential risk.
  • Lactation: It is unknown if the drug is excreted in human milk; caution should be exercised when administered to a nursing woman.
Advertisements

What should I know about interactions with other medicines?

The official regulatory profile for isosorbide mononitrate is structured around the risk of additive pharmacodynamic effects that can lead to severe hypotension.

Interaction Scope Description
Contraindicated Combinations Co-administration with Phosphodiesterase Type 5 (PDE5) Inhibitors (e.g., sildenafil, tadalafil) and Soluble Guanylate Cyclase (sGC) Stimulators (riociguat) is strictly prohibited. This restriction is mandatory due to the documented potential for profound, life-threatening potentiation of the blood pressure lowering effects.
Pharmacodynamic Potentiation Concurrent use with alcohol may result in additive vasodilatory effects, which can increase the frequency of light-headedness. Other antihypertensive agents or vasodilators may also potentiate hypotensive effects due to additive pharmacodynamic action.
Exposure Modification Co-administration with dihydroergotamine is noted in regulatory documents as potentially increasing the bioavailability of dihydroergotamine, which may enhance its effects. The label also notes that certain Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may diminish the therapeutic response.
Regulatory Constraints The absolute contraindication with PDE5 inhibitors necessitates a mandatory time separation (e.g., 24 to 48 hours) before nitrate administration can safely occur. Caution is explicitly warranted in patients with severe hepatic or renal impairment.
Advertisements

Mechanism of Action

ℯ Molecular Action: Activating the cGMP Signaling Pathway

Isosorbide mononitrate operates as a prodrug, releasing the signaling molecule nitric oxide (NO) within the vascular smooth muscle. This NO binds to and activates the enzyme soluble guanylate cyclase (sGC), triggering a cascade that increases the cellular messenger cGMP . This mechanism directly relaxes vascular smooth muscle by reducing intracellular calcium, initiating the process of widespread vasodilation.


Hemodynamic Effect: Modulation of Cardiac Preload

The resulting vasodilation preferentially affects the venous capacitance vessels, leading to blood pooling in the peripheral circulation. This action significantly reduces the volume and pressure of blood returning to the heart, a physiological effect known as lowering cardiac preload . By reducing preload, the drug mechanism reduces cardiac workload and the demand for oxygen by the myocardial tissue.


⏱ Mechanistic Constraint: Onset Kinetics and Tolerance

The mechanism's dependence on an initial bioactivation step requires time for the NO-cGMP cascade to fully develop, resulting in a slow onset of action. Furthermore, continuous, uninterrupted exposure can lead to nitrate tolerance, a physiological constraint where the mechanism's responsiveness is attenuated due to depletion of necessary cofactors or desensitization of the sGC system.

Advertisements

Dosage and Administration Information

The use of isosorbide mononitrate is defined by a strict, non-continuous dosing regimen required to prevent the development of pharmacological tolerance.

Administration Scope

Feature Guideline
Route of administration Oral administration only.
Dosing schedule Immediate-Release (IR): Typically 20 mg twice daily (BID), with the two doses separated by 7 hours to ensure a daily nitrate-free interval. Extended-Release (ER): Typically 30 mg or 60 mg once daily (QD), administered in the morning upon arising. Maximum doses of 240 mg once daily have been documented.
Timing in relation to meals Can be taken with or without food, as food does not significantly affect the drug's bioavailability.
Preparation requirements Tablets must be swallowed whole with fluid. Extended-release tablets must not be chewed, crushed, or split to maintain the controlled-release mechanism.
Age-group rules Older Adults (≥65 years): No routine dose adjustment is required, though initiating therapy at the low end of the dosing range is advised. Pediatrics (<18 years): Safety and efficacy have not been established.

Special Procedural Conditions

  • Tolerance Protocol: All dosing schedules, whether twice-daily or once-daily, must incorporate a daily drug-free interval (typically 10 to 17 hours) to maintain antianginal efficacy.
  • Discontinuation: Therapy should not be stopped abruptly; the dosage and frequency must be tapered gradually if discontinuation is required.

This protocol mandates an asymmetric dosing pattern and specific handling of the oral tablet forms, establishing the foundation for the long-term use of the medication.

Advertisements

Recent Clinical Evidence

Evidence for Chronic Stable Angina Prophylaxis

Research has primarily focused on evaluating isosorbide mononitrate for use in contexts related to conditions related to the prevention of chronic stable angina pectoris. The primary evidence is derived from short-term randomized controlled trials (RCTs) involving adult patients with a confirmed diagnosis of stable angina due to coronary artery disease. Researchers in these trials were used in research exploring how symptoms change over time by measuring surrogate endpoints, which are objective indicators that reflect a patient’s condition but are not direct, long-term health outcomes.

The primary outcomes examined in this research focused on two main areas: functional capacity and symptom patterns. Functional capacity was measured using standardized exercise testing, where studies monitored physiological strain or stress. Key outcomes included documented changes in the time patients sustained exercise when measured against pre-defined clinical markers. Symptom patterns were monitored by tracking the frequency of anginal episodes and the corresponding use of short-acting acute-relief medications, with research highlights measured during the study period.

However, a key challenge that research has consistently addressed is the potential for changes in measured functional effect when the agent is used continuously over 24 hours, a phenomenon known as tolerance. Overall, the existing evidence provides insight into short-term changes, but the studies often relied on surrogate markers such as exercise and symptom measurements.


What Is Still Uncertain About the Research Record

While the short-term controlled trials provided the initial framework, data for long-term outcomes remain limited. The follow-up durations for the most definitive RCTs were limited, often lasting only a few weeks. This means that the long-term functional effects are not well characterized by the most rigorous study types.

Furthermore, the research has not established whether short-term functional measurements correlate with long-term survival or cardiovascular events. These hard cardiac outcomes remain an area of limited information. Research provides context but not individual predictions, and studies contribute to the broader evidence landscape, but do not establish individual outcomes.

Key Studies & References

  1. Isosorbide Mononitrate Drug Label and Package Insert (e.g., Extended Release)
  2. Isosorbide Mononitrate: StatPearls [Internet] - Clinical Pharmacology and Antianginal Efficacy
  3. NICE Guideline: Stable Angina: Management (for context on clinical usage and evidence base)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Isocor (isosorbide mononitrate) (FAQ)

Q: How quickly does Isocor start working after I take it?

A: Isocor (isosorbide mononitrate) is described in official product information as working too slowly to relieve chest pain that has already started. This medication is intended for prevention and consistent support. The medication is therefore not indicated for the treatment of an acute angina attack, according to its official label.

Q: How long does the effect of one Isocor tablet last?

A: The extended-release formulation of Isocor is designed to provide its effects for an extended duration. According to regulatory documents, the effect can last for 8 to 10 hours or more. This profile supports its role in a preventative dosing schedule as outlined in official documents.

Q: Can I take Isocor if I also take a blood pressure medicine?

A: Official information indicates that taking Isocor with other medicines that lower blood pressure, such as antihypertensive agents or other vasodilators, can have additive effects. This combination might cause an excessive lowering of blood pressure. The combination of these medications is typically managed by a healthcare provider to monitor for effects.

Q: Does Isocor interact with common over-the-counter pain relievers?

A: Regulatory documents note that taking the medication with certain Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may potentially reduce the therapeutic response of Isocor. Because many common over-the-counter pain relievers are NSAIDs, it is important for patients to discuss the use of pain relievers with a healthcare professional.

Q: Can a person develop a tolerance to Isocor over time?

A: Yes, official documents describe that continuous, uninterrupted exposure to the drug can lead to nitrate tolerance—a temporary loss of the medicine's antianginal efficacy. For this reason, all approved dosing regimens, as described in official labels, incorporate a daily drug-free interval to help prevent this tolerance.

Q: What does the official drug label say about missing a dose?

A: Official patient information describes taking a missed dose as soon as it is remembered. However, if it is almost time for the next dose, the missed dose should be skipped entirely. The guidance cautions against taking two doses at the same time to compensate for a missed one.

Q: Are there any warnings about operating machinery or driving while taking Isocor?

A: Official information states that Isocor can sometimes cause a drop in blood pressure, which may lead to dizziness or light-headedness. Official documents contain warnings that patients affected by dizziness should use caution when driving or operating hazardous machinery.

Q: Is Isocor the same kind of medicine as nitroglycerin?

A: Both Isocor and nitroglycerin (glyceryl trinitrate) are classified as nitrate vasodilators and are used for angina. Isocor is intended for prevention and consistent management, while nitroglycerin is typically used for the immediate relief of acute symptoms.

Q: What is the difference between Isocor and isosorbide dinitrate?

A: Isocor contains the active ingredient isosorbide mononitrate, which is described in pharmacological studies as the active metabolite of isosorbide dinitrate. The mononitrate form is cited as being engineered for a more predictable oral absorption profile, supporting its role in stable, long-term therapeutic regimens.

Q: Is it normal to get a headache after taking Isocor?

A: Headache is listed in official sources as a very common adverse reaction, meaning it affects many people who take the medication. It is often experienced at the beginning of treatment and is listed as a frequent effect related to the drug's mechanism of action.

Q: Can Isocor be taken if I have kidney issues?

A: Regulatory documents state that caution is warranted in patients with severe renal (kidney) impairment. The drug's safety profile advises that if a person has decreased kidney function, the dose selection may need to be managed cautiously by a healthcare provider.

Q: Are there any specific foods or drinks to avoid while taking Isocor?

A: Official patient information notes that Isocor can generally be taken with or without food. However, co-administration with alcohol may lead to an excessive lowering of blood pressure, which can increase the frequency of light-headedness or dizziness.

Q: Is there a link between Isocor and changes in vision?

A: Official reports of adverse effects list blurred vision and diplopia (double vision) among the reported reactions. Changes in vision are generally noted as a symptom to be reported to a healthcare provider.

Q: Are there any common supplements that should not be taken with Isocor?

A: Regulatory warnings indicate that patients should inform their clinician of all products being taken, including vitamin and herbal supplements, as these may interact with the drug. The potential for interaction with specific supplements should be reviewed by a professional.

Q: What does Isocor do to the arteries in the heart?

A: In addition to relaxing peripheral veins to reduce the heart's workload, the drug's mechanism of action includes a direct dilatory (widening) effect on the coronary arteries. This action is described in official pharmacological information as helping to improve blood flow and oxygen supply to the heart muscle.

Q: Can people with low blood pressure safely take Isocor?

A: The medication is contraindicated (must not be used) in patients with severe hypotension (very low blood pressure). It is also recommended to be used with caution in patients who have pre-existing low blood pressure, as the medication is a vasodilator and could potentially further reduce blood pressure.

Q: Can Isocor cause problems with sleeping (insomnia)?

A: While regulatory sources list somnolence (drowsiness) as a reported adverse effect, insomnia (difficulty sleeping) is not specifically listed in the common side effect profiles. Changes in sleep patterns are typically discussed with a healthcare provider.

Q: Can Isocor interact with herbal products like St. John's Wort?

A: Official warnings state that herbal products have the potential to interact with Isocor. Consultation with a healthcare provider or pharmacist is generally necessary to review the use of specific herbal products, such as St. John's Wort.

Advertisements

How should Isocor (isosorbide mononitrate) be stored and disposed of?

How to Store and Dispose of Isocor (Isosorbide Mononitrate)

The medicine must be stored at controlled room temperature, typically maintained between 15 C and 30 C (59 F and 86 F). Isocor requires protection from environmental extremes; it must be stored in a dry place and kept from freezing or exposure to direct light and excessive moisture. Keep the medication in a closed container and ensure it is tightly closed when not in use. As a mandatory safety requirement, always store the product out of the reach of children.

Regarding disposal, do not keep outdated medicine. Users must ask a healthcare professional how to dispose of any unused or expired product to ensure disposal is done in accordance with local, state, or national legislation.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Isocor (isosorbide mononitrate) found in:

A-Z Index: